Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

J Baselga, A Cervantes, E. Martinelli, I. Chirivella, K. Hoekman, H.I. Hurwitz, D.I. Jodrell, P. Hamberg, E. Casado, P. Elvin, A. Swaisland, R. Iacona, J. Tabernero

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)4876-4883
JournalClinical Cancer Research
Volume16
Issue number19
DOIs
Publication statusPublished - 2010

Cite this

Baselga, J., Cervantes, A., Martinelli, E., Chirivella, I., Hoekman, K., Hurwitz, H. I., ... Tabernero, J. (2010). Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research, 16(19), 4876-4883. https://doi.org/10.1158/1078-0432.CCR-10-0748
Baselga, J ; Cervantes, A ; Martinelli, E. ; Chirivella, I. ; Hoekman, K. ; Hurwitz, H.I. ; Jodrell, D.I. ; Hamberg, P. ; Casado, E. ; Elvin, P. ; Swaisland, A. ; Iacona, R. ; Tabernero, J. / Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 19. pp. 4876-4883.
@article{948a1aa085e64a62986878ad43267392,
title = "Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors",
author = "J Baselga and A Cervantes and E. Martinelli and I. Chirivella and K. Hoekman and H.I. Hurwitz and D.I. Jodrell and P. Hamberg and E. Casado and P. Elvin and A. Swaisland and R. Iacona and J. Tabernero",
year = "2010",
doi = "10.1158/1078-0432.CCR-10-0748",
language = "Undefined/Unknown",
volume = "16",
pages = "4876--4883",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

Baselga, J, Cervantes, A, Martinelli, E, Chirivella, I, Hoekman, K, Hurwitz, HI, Jodrell, DI, Hamberg, P, Casado, E, Elvin, P, Swaisland, A, Iacona, R & Tabernero, J 2010, 'Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors' Clinical Cancer Research, vol. 16, no. 19, pp. 4876-4883. https://doi.org/10.1158/1078-0432.CCR-10-0748

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. / Baselga, J; Cervantes, A; Martinelli, E.; Chirivella, I.; Hoekman, K.; Hurwitz, H.I.; Jodrell, D.I.; Hamberg, P.; Casado, E.; Elvin, P.; Swaisland, A.; Iacona, R.; Tabernero, J.

In: Clinical Cancer Research, Vol. 16, No. 19, 2010, p. 4876-4883.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

AU - Baselga, J

AU - Cervantes, A

AU - Martinelli, E.

AU - Chirivella, I.

AU - Hoekman, K.

AU - Hurwitz, H.I.

AU - Jodrell, D.I.

AU - Hamberg, P.

AU - Casado, E.

AU - Elvin, P.

AU - Swaisland, A.

AU - Iacona, R.

AU - Tabernero, J.

PY - 2010

Y1 - 2010

U2 - 10.1158/1078-0432.CCR-10-0748

DO - 10.1158/1078-0432.CCR-10-0748

M3 - Article

VL - 16

SP - 4876

EP - 4883

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -